Licenses and Other Agreements - Additional Information (Details) - USD ($)	1 Months Ended		3 Months Ended		6 Months Ended
	Jan. 31, 2020	Nov. 30, 2017	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
License Agreements [Line Items]
Research and development			$ 20,856,000	$ 7,781,000	$ 32,305,000	$ 13,502,000
Duke University
License Agreements [Line Items]
Sale of licensed products or services					0
Fees payment					300,000
Nonroyalty payment received					1,000,000.0
Research and development			0	300,000	0	300,000
Wacker
License Agreements [Line Items]
Research and development			100,000	$ 0	200,000	$ 0
Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Research and development			$ 0		100,000
License agreement upfront payment	$ 100,000
Maximum | Achievement Of Clinical Development And Regulatory Milestones | Duke University
License Agreements [Line Items]
Potential milestones payment					2,200,000
Maximum | Commercial Milestones | Duke University
License Agreements [Line Items]
Potential milestones payment					400,000
Maximum | Commercial Milestones | Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Potential milestones payment	142,500,000
Maximum | Achievement Of Certain Development And Intellectual Property Milestones | Viamet Pharmaceuticals Holdings, LLC
License Agreements [Line Items]
Potential milestones payment	$ 5,100,000
Minimum | Duke University
License Agreements [Line Items]
Aggregate royalties payment					$ 200,000
MedImmune Limited | Maximum | Achievement Of Clinical Development And Regulatory Milestones
License Agreements [Line Items]
Potential milestones payment		$ 18,000,000.0
MedImmune Limited | Maximum | Commercial Milestones
License Agreements [Line Items]
Potential milestones payment		$ 50,000,000.0